Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon Cancer

Diagnostic Molecular Pathology

Volumn 19, Issue 1, 2010, Pages 20-27

  Beaulieu, Martin ^a   Desaulniers, Marie ^a   Bertrand, Nicolas ^a   Deschesnes, Réna G ^a   Beaudry, Guillaume ^a   Garon, Geneviève ^a   Haince, Jean François ^a   Houde, Michel ^a   Holzer, Timothy J ^a  

^a DiagnoCure Inc   (Canada)

Author keywords

Colon cancer; GCC; LN metastases

Indexed keywords

GUANYLATE CYCLASE; MESSENGER RNA;

ANALYTIC METHOD; ARTICLE; CANCER CELL; CANCER STAGING; COLON CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

COLONIC NEOPLASMS; FIXATIVES; FORMALDEHYDE; GUANYLATE CYCLASE; HUMANS; LYMPH NODES; PARAFFIN EMBEDDING; PATHOLOGY, MOLECULAR; RECEPTORS, PEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE FIXATION;

EID: 77749326540     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181ad5ac3     Document Type: Article

References (23)

1. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
2. Compton CC. Optimal pathologic staging: Defining stage II disease. Clin Cancer Res. 2007;13:6862s-6870s.
3. Bilchik AJ, Hoon DS, Saha S, et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg. 2007;246:568-577.
4. Frick GS, Pitari GM, Weinberg DS, et al. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert RevMol Diagn. 2005;5:701-713.
5. Schulz S, Hyslop T, Haaf J, et al. A validated quantitative assay to Detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res. 2006;12:4545-4552.
6. Noura S, Yamamoto H, Ohnishi T, et al. Comparative Detection of lymph noDe micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol. 2002;20:4232-4241.
7. Noura S, Yamamoto H, Miyake Y, et al. Immunohistochemical assessment of localization and frequency of micrometastases in lymph noDes of colorectal cancer. Clin Cancer Res. 2002;8:759-767.
8. Miyake Y, Yamamoto H, Fujiwara Y, et al. Extensive micrometastases to lymph noDes as a marker for rapid recurrence of colorectal cancer: a study of lymphatic mapping. Clin Cancer Res. 2001;7:1350-1357.
9. Iddings D, Ahmad A, Elashoff D, et al. The prognostic effect of micrometastases in previously staged lymph noDe negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol. 2006;13: 1386-1392.
10. Burdy G, Panis Y, Alves A, et al. IDentifying patients with T3-T4 noDe-negative colon cancer at high risk of recurrence. Dis Colon Rectum. 2001;44:1682-1688.
11. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
12. Bustin SA, Siddiqi S, Ahmed S, et al. Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph noDes may not predict treatment failure in colorectal cancer patients. Int J Cancer. 2004;108:412-417.
13. Pitari GM, Li P, Lin JE, et al. The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther. 2007;82:441-447.
14. Parkinson SJ, Alekseev AE, Gomez LA, et al. Interruption of Escherichia coli heat-stable enterotoxin-induced guanylyl cyclase signaling and associated chloriDe current in human intestinal cells by 2-chloroaDenosine. J Biol Chem. 1997;272:754-758.
15. Godfrey TE, Kim SH, Chavira M, et al. Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedDed tissues using 50 nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn. 2000;2:84-91.
16. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedDed tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004;164:35-42.
17. Specht K, Richter T, Muller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffinembedDed tumor tissue. Am J Pathol. 2001;158:419-429.
18. Oberli A, Popovici V, Delorenzi M, et al. Expression profiling with RNA from formalin-fixed, paraffin-embedDed material. BMC Med Genomics. 2008;1:9.
19. Birbe R, Palazzo JP, Walters R, et al. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and aDenocarcinoma of the gastrointestinal tract. Hum Pathol. 2005;36:170-179.
20. Kloeters O, Friess H, Giese N, et al. Uroguanylin inhibits proliferation of pancreatic cancer cells. Scand J Gastroenterol. 2008;43:447-455.
21. Carrithers SL, Barber MT, Biswas S, et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA. 1996;93: 14827-14832.
22. Bilchik AJ, Saha S, Wiese D, et al. Molecular staging of early colon cancer on the basis of sentinel noDe analysis: a multicenter phase II trial. J Clin Oncol. 2001;19:1128-1136.
23. Waldman SA, Hyslop T, Schulz S, et al. Association of GUCY2C expression in lymph noDes with time of recurrence and disease-free survival in pNO colorectal cancer. JAMA. 2009;301:745-752.